Human papillomavirus: the case for a gender-neutral vaccination programme

  Human papillomaviruses (HPV) are a large family of double-stranded DNA viruses that infect skin and mucosal cells [1]. Of the more than 100 recognised genotypes, at least 13 are considered to be oncogenic (or ‘high-risk’). The two most common of these, i.e. type 16 and 18, are known to cause approximately 70 per cent of all cervical cancers. Oncogenic HPVs have also been implicated as the aetiological agents in squamous cell carcinoma of the anus, genitals and the head and neck.